Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 23, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 781,750 Ordinary Shares of 25 pence each.
- Purchase Date: November 23, 2012.
- Price Range: Highest price paid was 1,349.0 pence per share; lowest price paid was 1,335.5 pence per share.
- Treasury Holdings: 490,140,427 shares held in Treasury (9.07% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 9.98% of total voting rights.
- Shares in Issue: 4,912,015,214 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 781,750 newly purchased shares. This action increases the percentage of voting rights held in Treasury to 9.98%.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (490,140,427) against subsequent filings to track the buyback program's progress.
- Confirm the calculation of voting rights (9.98%) based on the total issued share capital excluding Treasury shares.
- Review the price paid (1,335.5 to 1,349.0 pence) relative to the market price on November 23, 2012, to assess execution efficiency.
- Check for any subsequent announcements regarding the settlement of the purchased shares.